头孢吡普
头孢吡普 性质
| 密度 | 2.00±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | Store at -20°C,unstable in solution, ready to use. |
| 溶解度 | 二甲基亚砜：5 mg/mL（9.35 mM） |
| 形态 | 固体 |
| 酸度系数(pKa) | 2.46±0.50(Predicted) |
| 颜色 | 浅黄至黄色 |
头孢吡普 用途与合成方法
MIC90: 2 μg/mL (MRSA)
Ceftobiprole has demonstrates activity against important gram-positive bacteria, including S. pneumonia (PRSP), Methicillin-resistant S. aureus (MRSA), and E. faecalis with MIC 90 values of 0.25, 2, and 2 mcg/mL, respectively. Ceftobiprole has also demonstrated potent in vitro activity against several clinical isolates of community-associated Methicillin-resistant S. aureus (CA-MRSA), S. aureus (VISA), and S. aureus (VRSA), with a minimum inhibitory concentration (MIC) of 2 mcg/mL. Ceftobiprole is highly active against S. aureus, withMICs ranging from 0.12 to 4 mg/L (only one resistant strain,MIC of 4 mg/L). Furthermore, Ceftobiprole is twice more active on Methicillin-susceptible S. aureus (MSSA) strains with MIC 50 and MIC 90 of 0.5 mg/L than on MRSA strains with MIC 50 and MIC 90 of 1 mg/L. Moreover, Panton-Valentine leukocidin (PVL)+MRSA are slightly more susceptible to Ceftobiprole (MIC 50 of 0.5 mg/L and MIC 90 of 1 mg/L) than PVL-MRSA (MIC 50 and MIC 90 of 1 mg/L).
头孢吡普 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-112579 | 1 mg | 1200 | ||
| 2024-11-08 | HY-112579 | 头孢吡普 | 209467-52-7 | 5mg | 3100 |
